Great Lakes Advisors LLC lessened its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 15.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 107,992 shares of the medical research company’s stock after selling 19,901 shares during the quarter. Great Lakes Advisors LLC’s holdings in Amgen were worth $39,107,000 at the end of the most recent reporting period.
Other institutional investors have also recently added to or reduced their stakes in the company. Compass Wealth Management LLC acquired a new position in Amgen during the second quarter worth $281,000. Danica Pension Livsforsikringsaktieselskab increased its stake in shares of Amgen by 6.5% in the 2nd quarter. Danica Pension Livsforsikringsaktieselskab now owns 36,716 shares of the medical research company’s stock worth $13,296,000 after acquiring an additional 2,225 shares during the last quarter. Oxbow Advisors LLC increased its stake in shares of Amgen by 0.8% in the 2nd quarter. Oxbow Advisors LLC now owns 11,698 shares of the medical research company’s stock worth $4,236,000 after acquiring an additional 92 shares during the last quarter. Cypress Asset Management Inc. TX raised its holdings in shares of Amgen by 6.8% during the 2nd quarter. Cypress Asset Management Inc. TX now owns 4,881 shares of the medical research company’s stock worth $1,768,000 after acquiring an additional 310 shares during the period. Finally, Main Street Financial Solutions LLC purchased a new position in shares of Amgen during the 2nd quarter worth $1,662,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.
Analyst Upgrades and Downgrades
A number of equities research analysts recently issued reports on AMGN shares. Freedom Capital raised shares of Amgen from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. Daiwa Securities Group decreased their target price on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating on the stock in a report on Wednesday, May 13th. Barclays raised their price target on shares of Amgen from $360.00 to $380.00 and gave the stock an “equal weight” rating in a report on Friday, August 14th. Bank of America increased their price objective on Amgen from $312.00 to $317.00 and gave the stock an “underperform” rating in a research report on Wednesday, August 5th. Finally, The Goldman Sachs Group set a $389.00 target price on Amgen in a research note on Friday, June 5th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have issued a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $379.36.
Amgen Price Performance
Shares of AMGN opened at $442.36 on Thursday. The firm has a 50-day simple moving average of $375.75 and a two-hundred day simple moving average of $360.76. The stock has a market cap of $239.15 billion, a PE ratio of 27.49, a P/E/G ratio of 3.95 and a beta of 0.41. Amgen Inc. has a 1-year low of $269.77 and a 1-year high of $443.20. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13.
Amgen (NASDAQ:AMGN – Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping the consensus estimate of $5.62 by $0.67. The firm had revenue of $10.05 billion for the quarter, compared to analyst estimates of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period in the prior year, the business posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, analysts forecast that Amgen Inc. will post 22.78 EPS for the current year.
Amgen Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be paid a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Friday, August 21st. Amgen’s dividend payout ratio is 62.65%.
Insider Buying and Selling at Amgen
In related news, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the transaction, the senior vice president owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. This represents a 28.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Rachna Khosla sold 2,000 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00. Following the sale, the senior vice president directly owned 6,404 shares in the company, valued at $2,642,098.28. This represents a 23.80% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 6,222 shares of company stock valued at $2,540,926. Company insiders own 0.85% of the company’s stock.
Trending Headlines about Amgen
Here are the key news stories impacting Amgen this week:
- Positive Sentiment: Amgen was highlighted as one of the best-performing U.S. large-cap drugmakers in 2026, outperforming peers Merck and Pfizer despite lacking an obesity drug. The comparison reinforces investor confidence in Amgen’s existing portfolio and operating execution. Which Drugmaker Stock Has Dominated in 2026: Merck, Pfizer, or Amgen?
- Positive Sentiment: Healthcare-sector strength and a rotation toward profitable drugmakers helped lift Amgen, while renewed enthusiasm for biotechnology also improved sentiment across the industry. Amgen Stock Surges as Healthcare Hits Record High
- Positive Sentiment: Argus raised its Amgen price target from $375 to $460 and maintained a “buy” rating, citing additional upside for the shares. Argus price-target update
- Neutral Sentiment: Amgen’s latest quarterly results beat consensus estimates for earnings and revenue, with revenue growth accelerating year over year. Full-year earnings guidance and expectations for continued growth remain important supports for the investment case.
- Neutral Sentiment: The obesity-drug market is becoming more selective, and Amgen is reportedly trimming some early-stage efforts. This could improve capital discipline, but it also highlights execution risk as the company competes in a crowded field. Obesity investing’s way forward, mapped
- Negative Sentiment: Although Cantor Fitzgerald and Mizuho raised their price targets, both retained “neutral” ratings and set targets below the current trading level, signaling valuation concerns after Amgen’s strong run. Analyst price-target updates
Amgen Profile
Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.
Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.
Featured Stories
- Five stocks we like better than Amgen
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
